Herpes zoster vaccination in systemic lupus erythematosus: the current status

References

• Johnson RW, Bouhassira D, Kassianos G, Leplège A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37. doi:10.1186/1741-7015-8-37.
   PubMed Web of Science ®Google Scholar
• Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018;41(1). Epub ahead of print
   PubMedGoogle Scholar
• Kawai K, Yawn BP. Risk factors for Herpes Zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92:1806–1821. doi:10.1016/j.mayocp.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Chakravarty EF, Michaud K, Katz R, Wolfe F. Increased incidence of herpes zoster among patients with systemic lupus erythematosus. Lupus. 2013;22:238–244. doi:10.1177/0961203312470186.
   PubMed Web of Science ®Google Scholar
• Doan HQ, Ung B, Ramirez-Fort MK, Khan F, Tyring SK. Zostavax: a subcutaneous vaccine for the prevention of herpes zoster. Expert Opin Biol Ther. 2013;13:1467–1477. doi:10.1517/14712598.2013.830101.
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JPA, Jayne DRW, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70:414–422. doi:10.1136/ard.2010.137216.
   PubMed Web of Science ®Google Scholar
• Harpaz R, Ortega-Sanchez IR, Seward JF. Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR–5):1–30.
   PubMedGoogle Scholar
• Cunningham AL. The herpes zoster subunit vaccine. Expert Opin Biol Ther. 2016;16:265–271. doi:10.1517/14712598.2016.1134481.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Mullane KM, Cornely OA, Boeckh MJ, Brown JW, Pergam SA, Trociukas I, Žák P, Craig MD, Papanicolaou GA, et al. V212 Protocol 001 Trial Team. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391:2116–2127. doi:10.1016/S0140-6736(18)30631-7.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Sullivan KM, Marty FM, Dadwal SS, Papanicolaou GA, Shea TC, Mossad SB, Andreadis C, Young J-AH, Buadi FK, et al. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–2929. doi:10.1182/blood-2014-04-573048.
   PubMed Web of Science ®Google Scholar
• Berkowitz EM, Moyle G, Stellbrink HJ, Schürmann D, Kegg S, Stoll M, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279–1287. doi:10.1093/infdis/jiu606.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Clinical practice: herpes zoster. N Engl J Med. 2013;369:255–263. doi:10.1056/NEJMcp1302674.
   PubMed Web of Science ®Google Scholar
• Yun H, Yang S, Chen L, Xie F, Winthrop K, Baddley JW, Saag KG, Singh J, Curtis JR. Risk of Herpes Zoster in autoimmune and inflammatory diseases: implications for vaccination. Arthritis Rheumatol. 2016;68:2328–2337. doi:10.1002/art.39670.
   PubMed Web of Science ®Google Scholar
• Nagasawa K, Yamauchi Y, Tada Y, Kusaba T, Niho Y, Yoshikawa H. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis. Ann Rheum Dis. 1990;49:630–633.
   PubMed Web of Science ®Google Scholar
• Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003;15:528–534.
   PubMed Web of Science ®Google Scholar
• Chen HH, Chen YM, Chen TJ, Lan JL, Lin CH, Chen DY. Risk of herpes zoster in patients with systemic lupus erythematosus: a three-year follow-up study using a nationwide population-based cohort. Clinics (Sao Paulo). 2011;66:1177–1182.
   PubMed Web of Science ®Google Scholar
• Borba EF, Ribeiro AC, Martin P, Costa LP, Guedes LK, Bonfá E. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus. J Clin Rheumatol. 2010;16:119–122. doi:10.1097/RHU.0b013e3181d52ed7.
   PubMed Web of Science ®Google Scholar
• Hata A, Kuniyoshi M, Ohkusa Y. Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study. Infection. 2011;39:537–544. doi:10.1007/s15010-011-0162-0.
   PubMed Web of Science ®Google Scholar
• Kahl LE. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol. 1994;21:84–86.
   PubMed Web of Science ®Google Scholar
• Chen D, Li H, Xie J, Zhan Z, Liang L, Yang X. Herpes zoster in patients with systemic lupus erythematosus: clinical features, complications and risk factors. Exp Ther Med. 2017;14:6222–6228. doi:10.3892/etm.2017.5297.
   PubMed Web of Science ®Google Scholar
• Hu SC, Yen FL, Wang TN, Lin YC, Lin CL, Chen GS. Immunosuppressive medication use and risk of herpes zoster (HZ) in patients with systemic lupus erythematosus (SLE): A nationwide case-control study. J Am Acad Dermatol. 2016;75:49–58. doi:10.1016/j.jaad.2015.12.059.
   PubMed Web of Science ®Google Scholar
• Manzi S, Kuller LH, Kutzer J, Pazin GJ, Sinacore J, Medsger TA Jr, Ramsey-Goldman R. Herpes zoster in systemic lupus erythematosus. J Rheumatol. 1995;22:1254–1258.
   PubMedGoogle Scholar
• Moutsopoulos HM, Gallagher JD, Decker JL, Steinberg AD. Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum. 1978;21:798–802.
   PubMed Web of Science ®Google Scholar
• Lee PP, Lee TL, Ho MH, Wong WH, Lau YL. Herpes zoster in juvenile-onset systemic lupus erythematosus: incidence, clinical characteristics and risk factors. Pediatr Infect Dis J. 2006;25:728–732. doi:10.1097/01.inf.0000226841.03751.1f.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284. doi:10.1056/NEJMoa051016.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su S-C, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54:922–928. doi:10.1093/cid/cir970.
   PubMed Web of Science ®Google Scholar
• Arvin AM. Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008;197(Suppl 2):S58–60. doi:10.1086/522123.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. ZOE-50 study group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. ZOE-70 study group. Efficacy of the Herpes Zoster Subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–1032. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Volpe S, Catteau G, Chlibek R, David MP, Richardus JH, Lal H, Oostvogels L, Pauksens K, Ravault S, et al. Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults. Hum Vaccin Immunother. 2018;14:1370–1377. doi:10.1080/21645515.2018.1442162.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Bresnitz E, Popmihajlov Z, Weinberg A, Liaw KL, Willis E, Curtis JR. Studies with herpes zoster vaccines in immune compromised patients. Expert Rev Vaccines. 2017;16:1217–1230. doi:10.1080/14760584.2017.1395703.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie F, Delzell E, Chen L, Winthrop KL, Lewis JD, Saag KG, Baddley JW, Curtis JR. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308:43–49. doi:10.1001/jama.2012.7304.
   PubMed Web of Science ®Google Scholar
• Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, Roberts V, James JA, Chakravarty EF. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40:1875–1880. doi:10.3899/jrheum.130170.
   PubMed Web of Science ®Google Scholar
• Bharucha T, Ming D, Breuer J. A critical appraisal of ‘Shingrix’, a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus. Hum Vaccin Immunother. 2017;13:1789–1797. doi:10.1080/21645515.2017.1317410.
   PubMed Web of Science ®Google Scholar
• Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W. CD1067 study investigators. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016;75:1909–1916. doi:10.1136/annrheumdis-2015-208562.
   PubMed Web of Science ®Google Scholar
• Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P, Illei GG, Drappa J, Wang L, Yoo S. CD1013 Study Investigators. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017;69:376–386. doi:10.1002/art.39962.
   PubMed Web of Science ®Google Scholar
• Crow MK. Type I interferon in the pathogenesis of lupus. J Immunol. 2014;192:5459–5468. doi:10.4049/jimmunol.1002795.
   PubMed Web of Science ®Google Scholar
• Willis ED, Woodward M, Brown E, Popmihajlov Z, Saddier P, Annunziato PW, Halsey NA, Gershon AA. Herpes zoster vaccine live: A 10 year review of post-marketing safety experience. Vaccine. 2017;35:7231–7239. doi:10.1016/j.vaccine.2017.11.013.
   PubMed Web of Science ®Google Scholar